title: Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes.
abstract: BACKGROUND
  Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with male breast cancer treated with eribulin. To our knowledge, this is the first report on the use or eribulin in this setting.
  
  
  METHODS
  Patients were retrospectively identified in 19 reference centers. All patients received eribulin treatment, according to the standard practice of each center. Data on the identified patients were collected using a standardized form and were then centrally reviewed by two experienced oncologists.
  
  
  RESULTS
  A total of 23 patients (median age, 64 years; range, 42-80) were considered. The median age at the time of diagnosis of breast cancer was 57 years (range, 42-74). HER2 status was negative in 14 patients (61%), and 2 patients (9%) had triple-negative disease. The most common metastatic sites were the lung (n= 14; 61%) and bone (n= 13; 56%). Eribulin was administered for a median of 6 cycles (range, 3-15). All patients reported at least stable disease; two complete responses (9%) were documented. Eribulin was well-tolerated, with only four patients (17%) reporting grade 3 adverse events and two (9%) with treatment interruptions because of toxicity. Eight subjects (35%) did not report any adverse event during treatment. For patients with a reported fatal event, the median overall survival from the diagnosis of metastatic disease was 65 months (range, 22-228).
  
  
  CONCLUSIONS
  Although hampered by all the limitations of any retrospective case series, the results of the present study suggest, for the first time, the use of eribulin as therapy for male breast cancer.
  
  
  CONCLUSIONS
  Evidence on the management and treatment of male breast cancer is eagerly awaited. Although hampered by all the limitations of any retrospective case series, the results of the present study suggest, for the first time, the use of eribulin as therapy for male breast cancer.
authors.affiliation: Oncologia Medica, Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Tumori "Giovanni Paolo II," Bari, Italy francescogiotta@libero.it.
authors.forename: Francesco
authors.initials: F
authors.lastname: Giotta
authors.affiliation: Oncologia Medica, Ospedale A. Murri, Fermo, Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Acito
authors.affiliation: U.O.S.D. Oncologia P.O. Avezzano, Avezzano, Italy.
authors.forename: Giampiero
authors.initials: G
authors.lastname: Candeloro
authors.affiliation: Oncologia, Ospedali Riuniti, Reggio Calabria, Italy.
authors.forename: Pietro
authors.initials: P
authors.lastname: Del Medico
authors.affiliation: Division of Medical Oncology, "Mons. R. Dimiccoli" Hospital, Barletta, Italy.
authors.forename: Gennaro
authors.initials: G
authors.lastname: Gadaleta-Caldarola
authors.affiliation: Ospedale Sacro Cuore di Gesú Fatebenefratelli, Benevento, Italy.
authors.forename: Guido
authors.initials: G
authors.lastname: Giordano
authors.affiliation: Ospedale di Circolo e Fondazione Macchi Varese, Varese, Italy.
authors.forename: Rossana
authors.initials: R
authors.lastname: Gueli
authors.affiliation: Columbus Clinic, Rome, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Lugini
authors.affiliation: Policlinico Umberto I, Rome, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Magri
authors.affiliation: San Bonifacio Hospital, Verona, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Mandarà
authors.affiliation: Humanitas Cancer Center, Rozzano, Italy.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Masci
authors.affiliation: San Giuseppe Moscati, ALS Taranto, Italy.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Pisconti
authors.affiliation: Ospedali Riuniti, Ancona, Italy.
authors.forename: Mirco
authors.initials: M
authors.lastname: Pistelli
authors.affiliation: Poliambulanza Brescia, Brescia, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Rizzi
authors.affiliation: Ospedale Civile di Latina, Latina, Italy.
authors.forename: Nello
authors.initials: N
authors.lastname: Salesi
authors.affiliation: Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Istituti di Ricovero e Cura a Carattere Scientifico, Meldola, Italy.
authors.forename: Alessio
authors.initials: A
authors.lastname: Schirone
authors.affiliation: Ospedale Valduce, Como, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Scognamiglio
authors.affiliation: Ospedale Israelitico, Rome, Italy.
authors.forename: Maria
authors.initials: M
authors.lastname: Tedeschi
authors.affiliation: San Raffaele Hospital, Milan, Italy.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Zucchinelli
keywords: Clinical practice; Eribulin; Male breast cancer; Treatment